Gilead Board approves two-for-one stock split
10 December 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that its Board of Directors has approved a two-for-one stock split...
List view / Grid view
10 December 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that its Board of Directors has approved a two-for-one stock split...
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
9 December 2012 | By Bristol-Myers Squibb Company
Results from Phase 2 open-label study...
9 December 2012 | By Sanofi
New data presented at American Society of Hematology Annual Meeting show activity against disease and symptom alleviation...
8 December 2012 | By Roche
Roche announced results from two studies...
8 December 2012 | By Roche
Roche announced updated survival results from the Phase III CLEOPATRA study...
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
7 December 2012 | By Abbott
Abbott expects to complete separation of AbbVie on Jan. 1, 2013...
7 December 2012 | By Hach Company
Hach Company is pleased to announce the release of the ASX 7200 Autosampler...
6 December 2012 | By Ballou PR
Distribution agreement...
6 December 2012 | By Johnson & Johnson
"We are pleased to present applications..."
5 December 2012 | By Roche
Roche and the IMI launch StemBANCC...
5 December 2012 | By Boehringer Ingelheim
"We are very pleased to partner with Apexigen..."
5 December 2012 | By Teva UK Limited
Teva UK Limited has been named the UK’s Generics Manufacturer of the Year for an unprecedented tenth time...
4 December 2012 | By Novartis
Healthcare experts assess psychosocial approaches and interventions...